[시장보고서]부인과 의약품 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료법별, 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

부인과 의약품 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료법별, 적응증별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics, By Indication, By Distribution Channel, By Region and Competition, 2020-2030F

상품코드 : 1878872

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 180 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 부인과 의약품 시장은 2024년에 62억 달러로 평가되었으며, 2030년까지 CAGR 7.78%로 성장하여 97억 2,000만 달러에 달할 것으로 예측됩니다.

부인과 의약품은 여성 생식기관에 특유한 질환을 진단, 치료 또는 예방하기 위해 개발된 의약품으로 생리불순, 불임부터 부인과 암, 갱년기 증상까지 다양한 질환을 포괄하고 있습니다. 시장 확대의 기반이 되는 주요 촉진요인으로는 자궁내막증, 다낭성난소증후군 등 부인과 질환의 전 세계적인 유병률 증가와 더불어 여성 건강에 대한 인식의 증가와 적극적인 대처를 꼽을 수 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	62억 달러
시장 규모 : 2030년	97억 2,000만 달러
CAGR : 2025-2030년	7.78%
가장 빠르게 성장하는 부문	호르몬요법
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 치료법별(비호르몬요법, 호르몬요법)
- 적응증별(피임, 부인과 감염증, 여성 불임, 폐경후 장애, 다낭성난소증후군, 골다공증, 부인과암, 자궁내막증, 기타)
- 유통 채널별(소매 약국, 병원 약국, 온라인 약국)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 부인과 의약품 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 부인과 의약품 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 부인과 의약품 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 부인과 의약품 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 부인과 의약품 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 부인과 의약품 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

Amgen Inc.
Novartis AG
Bayer AG
Merck & Co., Inc.
Eli Lilly and Company
Pfizer Inc.
Abbott Laboratories Inc.
AbbVie Inc.
GlaxoSmithKline Plc
Lupin Limited

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Gynecology Drugs Market, valued at USD 6.20 Billion in 2024, is projected to experience a CAGR of 7.78% to reach USD 9.72 Billion by 2030. Gynecology drugs are pharmaceutical agents developed to diagnose, treat, or prevent conditions specific to the female reproductive system, encompassing a range of disorders from menstrual irregularities and infertility to gynecological cancers and menopausal symptoms. The market's expansion is fundamentally supported by several drivers, including the escalating global prevalence of gynecological disorders such as endometriosis and polycystic ovary syndrome, alongside a heightened awareness and proactive approach to women's health.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.20 Billion
Market Size 2030	USD 9.72 Billion
CAGR 2025-2030	7.78%
Fastest Growing Segment	Hormonal Therapy
Largest Market	North America

Key Market Drivers

The global gynecology drugs market experiences substantial expansion driven by the rising prevalence of gynecological disorders worldwide. Conditions such as endometriosis, polycystic ovary syndrome, and uterine fibroids affect a significant portion of the female population, creating an imperative demand for effective pharmaceutical interventions. This increasing disease burden necessitates ongoing research and development into novel therapeutic solutions to manage symptoms, improve quality of life, and address underlying pathologies. According to the World Health Organization, in March 2023, endometriosis alone impacts approximately 10 percent, or 190 million, of reproductive age women and girls globally, highlighting the widespread need for treatments. This pervasive presence of gynecological ailments underpins the consistent requirement for diagnostic and treatment drugs, forming a fundamental driver for market growth.

Key Market Challenges

The substantial cost associated with developing and obtaining regulatory approval for novel gynecological therapeutics presents a significant impediment to the growth of the Global Gynecology Drugs Market. The extensive research and development (R&D) phases, coupled with the rigorous and often protracted regulatory pathways, necessitate considerable financial outlays. This elevated expenditure increases the financial risk for pharmaceutical companies, particularly when considering specific gynecological conditions that may affect smaller patient populations or require highly specialized, complex therapeutic approaches.

Key Market Trends

This trend fundamentally transforms the development and application of gynecological drugs by tailoring treatments to individual patient genetic profiles and disease characteristics. This precision approach allows for more effective interventions with reduced side effects, moving beyond traditional broad-spectrum pharmaceuticals. The market emphasizes identifying specific biomarkers that predict drug response or disease progression, particularly in gynecologic oncology. Venture capital funding in women's health recorded a single-quarter high of $435 million in the third quarter of 2023, according to a Silicon Valley Bank report, indicating robust financial backing for specialized therapeutic advancements. This drives the development of novel diagnostics and companion therapies, leading to more targeted options for patients.

Key Market Players

Amgen Inc.
Novartis AG
Bayer AG
Merck & Co., Inc.
Eli Lilly and Company
Pfizer Inc.
Abbott Laboratories Inc.
AbbVie Inc.
GlaxoSmithKline Plc
Lupin Limited

Report Scope:

In this report, the Global Gynecology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gynecology Drugs Market, By Therapeutics:

Non-Hormonal Therapy
Hormonal Therapy

Gynecology Drugs Market, By Indication:

Contraception
Gynecology Infections
Female Infertility
Postmenopausal disorders
Polycystic Ovary Syndrome
Osteoporosis
Gynecology Cancer
Endometriosis
Others

Gynecology Drugs Market, By Distribution Channel:

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Gynecology Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gynecology Drugs Market.

Available Customizations:

Global Gynecology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gynecology Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Therapeutics (Non-Hormonal Therapy, Hormonal Therapy)
- 5.2.2. By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others)
- 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Gynecology Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Therapeutics
- 6.2.2. By Indication
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Gynecology Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Therapeutics
    - 6.3.1.2.2. By Indication
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Gynecology Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Therapeutics
    - 6.3.2.2.2. By Indication
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Gynecology Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Therapeutics
    - 6.3.3.2.2. By Indication
    - 6.3.3.2.3. By Distribution Channel

7. Europe Gynecology Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Therapeutics
- 7.2.2. By Indication
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Gynecology Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Therapeutics
    - 7.3.1.2.2. By Indication
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Gynecology Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Therapeutics
    - 7.3.2.2.2. By Indication
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Gynecology Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Therapeutics
    - 7.3.3.2.2. By Indication
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Gynecology Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Therapeutics
    - 7.3.4.2.2. By Indication
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Gynecology Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Therapeutics
    - 7.3.5.2.2. By Indication
    - 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Gynecology Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Therapeutics
- 8.2.2. By Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Gynecology Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Therapeutics
    - 8.3.1.2.2. By Indication
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Gynecology Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Therapeutics
    - 8.3.2.2.2. By Indication
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Gynecology Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Therapeutics
    - 8.3.3.2.2. By Indication
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Gynecology Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Therapeutics
    - 8.3.4.2.2. By Indication
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Gynecology Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Therapeutics
    - 8.3.5.2.2. By Indication
    - 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Gynecology Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Therapeutics
- 9.2.2. By Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Gynecology Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Therapeutics
    - 9.3.1.2.2. By Indication
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. UAE Gynecology Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Therapeutics
    - 9.3.2.2.2. By Indication
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. South Africa Gynecology Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Therapeutics
    - 9.3.3.2.2. By Indication
    - 9.3.3.2.3. By Distribution Channel

10. South America Gynecology Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Therapeutics
- 10.2.2. By Indication
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Gynecology Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Therapeutics
    - 10.3.1.2.2. By Indication
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Colombia Gynecology Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Therapeutics
    - 10.3.2.2.2. By Indication
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Argentina Gynecology Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Therapeutics
    - 10.3.3.2.2. By Indication
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Gynecology Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Amgen Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Bayer AG
15.4. Merck & Co., Inc.
15.5. Eli Lilly and Company
15.6. Pfizer Inc.
15.7. Abbott Laboratories Inc.
15.8. AbbVie Inc.
15.9. GlaxoSmithKline Plc
15.10. Lupin Limited